Engaging Newly Diagnosed Men About Cancer Treatment Options (ENACT)
Prostatic Neoplasms
About this trial
This is an interventional other trial for Prostatic Neoplasms focused on measuring Prostatic neoplasms, Oncotype DX, Treatment Decisions
Eligibility Criteria
Inclusion Criteria:
- Men with newly diagnosed prostate cancer who are categorized as Very Low, Low, or Intermediate risk by NCCN criteria;
- Are age 76 or younger
Exclusion Criteria:
- Men who are categorized as High or Very High risk by NCCN criteria;
- Men who have already received counseling from their urologist about their treatment options and have decided to undergo treatment, active surveillance, or watchful waiting;
- Men age 77 or older
Sites / Locations
- Jesse Brown V. A. Medical Center
- John H. Stroger Hospital of Cook County
- University of Illinois at Chicago
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
Standard NCCN counseling
Standard NCCN counseling and Oncotype DX results
National Comprehensive Cancer Network (NCCN) counseling uses recommendations based on currently-accepted approaches to cancer treatment.
National Comprehensive Cancer Network (NCCN) counseling uses recommendations based on currently-accepted approaches to cancer treatment. The result provided by the Oncotype DX prostate test is called a Genomic Prostate Score (GPS). The GPS provides important information about how aggressive a man's cancer is based on the biology of the man's individual tumor.